WO2023007404 - PUDEXACIANINIUM FOR NIRF IMAGING
National phase entry:
Publication Number
WO/2023/007404
Publication Date
02.02.2023
International Application No.
PCT/IB2022/056957
International Filing Date
27.07.2022
Title **
[English]
PUDEXACIANINIUM FOR NIRF IMAGING
[French]
PUDEXACIANINIUM POUR IMAGERIE PAR FLUORESCENCE DANS LE PROCHE INFRAROUGE (NIRF)
Applicants **
ASTELLAS PHARMA INC.
Inventors
SAITO, Masako
KOMATSU, Kanji
TAKUSAGAWA, Shin
DELGADO-HERRERA, Leticia
Priority Data
63/226,534
28.07.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1969 | |
| EPO | Filing, Examination, Granting | 8131 | |
| Japan | Filing, Examination, Granting | 2100 | |
| South Korea | Filing, Examination, Granting | 1932 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
18,872
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Intraoperative ureter identification helps reduce the risk of ureteral injury. In this first-in-human phase 1 study, Pudexacianinium chloride was administered intravenously in healthy adult participants as a single bolus dose. This invention is related to a new amount of administration using Pudexacianinium or pharmaceutically acceptable salt thereof for intraoperative NIRF ureter visualization.[French]
Selon l'invention, l'identification de l'uretère peropératoire aide à réduire le risque de lésion de l'uretère. Dans cette première étude de phase 1 chez l'homme, du chlorure de pudexacianinium a été administré par voie intraveineuse à des participants adultes en bonne santé sous forme de dose unique en bolus. La présente invention concerne une nouvelle quantité d'administration utilisant du pudexacianinium ou un sel pharmaceutiquement acceptable de celui-ci dans la visualisation peropératoire NIRF de l'uretère .